DERM News and Press, Journey Medical Corporation From 06/09/25

National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz., June 09, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Me...

2025-06-06 17:26:17 ET ... Read the full article on Seeking Alpha For further details see: Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside

Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to approve the transaction to take place on May 28, 2025 F...

2025-05-15 10:28:23 ET Journey Medical Corporation (NASDAQ: DERM) is one of today’s top gainers. The company’s shares have moved 21.27% on the day to $7.24. Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the ...

2025-05-15 02:49:19 ET More on Journey Medical Journey Medical Corporation (DERM) Q1 2025 Earnings Call Transcript Journey Medical Corporation 2025 Q1 - Results - Earnings Call Presentation Journey Medical Corporation (DERM) Q4 2024 Earnings Call Transcript J...

2025-05-14 19:09:07 ET More on Journey Medical Journey Medical Corporation (DERM) Q1 2025 Earnings Call Transcript Journey Medical Corporation 2025 Q1 - Results - Earnings Call Presentation Journey Medical Corporation (DERM) Q4 2024 Earnings Call Transcript S...

2025-05-14 19:08:30 ET Journey Medical Corporation (DERM) Q1 2025 Earnings Conference Call May 14, 2025, 04:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and Chief Executive Officer Josep...

Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results f...

Aeva Technologies Inc. (AEVA) is expected to report $-0.59 for Q1 2025 Brasilagro Brazilian Agric Real Estate Co Sponsored ADR (Brazil) (LND) is expected to report for Q3 2025 Omron Corporation ADR (OMRNY) is expected to report for Q4 2025 Sezzle Inc. (SEZL) is expected to report $0.3...

2025-05-13 18:48:09 ET Journey Medical Corporation (DERM) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 4.40%. The average open to low on the day of earnings was -7.81%. The average op...